Bifogade filer
Kurs
+31,58%
Likviditet
1,68 MNOK
Prenumeration
Kalender
Est. tid* | ||
2025-08-28 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2025-06-05 | - | Årsstämma |
2025-04-10 | - | Bokslutskommuniké 2024 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-06-19 | - | Årsstämma |
2024-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2024-04-25 | - | Bokslutskommuniké 2023 |
2023-10-04 | - | Split CRNA 30:1 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2023-03-09 | - | Extra Bolagsstämma 2023 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-20 | - | Årsstämma |
2022-04-07 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-25 | - | Extra Bolagsstämma 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-18 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-03-18 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2021-03-17 | - | Årsstämma |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-04-30 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2020-04-29 | - | Årsstämma |
2020-03-11 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-04-10 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2019-04-09 | - | Årsstämma |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-01 | - | Kvartalsrapport 2018-Q3 |
2018-08-23 | - | Kvartalsrapport 2018-Q2 |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-04-12 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2018-04-11 | - | Årsstämma |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-04-05 | - | Årsstämma |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-12 | - | Kvartalsrapport 2016-Q1 |
2016-04-14 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2016-04-13 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Bioteknik |
Oslo, 27 May 2025: Reference is made to the notice of the annual general meeting of Circio Holding ASA (the "Company") published on 15 May 2025 and the annual general meeting ("AGM") to be held on Thursday 5 June 2025 at 10:00 hours (CEST).
The board of directors has resolved to withdraw the proposals under agenda item 10 "Reverse Share Split" and agenda item 11 "Share Capital Decrease". Consequently, agenda item 10 and agenda item 11 will not be subject to voting at the AGM.
In addition, the board of directors proposes that the previously proposed board authorizations in agenda items 12 "General board authorization to increase the share capital" and agenda item 13 "Board authorization to increase the share capital in connection with share incentive arrangements and grant of restricted stock units to the board of directors as remuneration" are adjusted to reflect the withdrawal of the reverse share split and the share capital decrease.
For agenda item 12, the board of directors proposes that it is granted an authorization to increase the Company's share capital by up to either 40% (agenda item 12.1), 30% (agenda item 12.2), or 20% (agenda item 12.3) of the Company's share capital as of the date of the general meeting.
For agenda item 13, the board of directors proposes that it is granted an authorisation to increase the Company's share capital by up to 10% of the Company's share capital as at the date of the general meeting.
An updated AGM registration and proxy form is attached to this announcement and is available for advance voting through the logging on to VPS Investor Services, by following link on the Company's webpage https://www.circio.com/en/annual-general-meeting-2025/. Please note that any advance votes cast on the items under agenda item 10 and agenda item 11 will be considered void. Any advance votes cast on agenda item 12 and 13 can be changed up until the applicable voting deadlines as given in the notice.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS -mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.